M.D. Anderson Cancer Center: Lymphoma, Follicular trials

The registry lists 18 Lymphoma, Follicular studies with M.D. Anderson Cancer Center as lead sponsor. 4 are open to participants now and 10 have results posted.

Phase 1 5Phase 2 16No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphomaNot yet recruitingNCT07783594Phase 2
• Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular LymphomaRecruitingNCT06108232Phase 2
• A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular LymphomaRecruitingNCT06043323Phase 2
• Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell TherapyRecruitingNCT04870853
• Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaCompletedNCT04432506Phase 2Results posted
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
• Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular LymphomaCompletedNCT02871219Phase 2Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymphomaActive, not recruitingNCT02446457Phase 2Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01995669Phase 1/2Results posted
• Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular LymphomaCompletedNCT00904722Phase 2Results posted
• Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular LymphomaTerminatedNCT00901927Phase 2Results posted
• Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin LymphomaCompletedNCT00695786Phase 2Results posted
• Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular LymphomaCompletedNCT00290511Phase 2Results posted
• ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT05025800Phase 1/2
• Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
• CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaWithdrawnNCT03579927Phase 1/2
• Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1